[{"address1": "4546 El Camino Real", "address2": "Suite B1", "city": "Los Altos", "state": "CA", "zip": "94022", "country": "United States", "phone": "650 284 4433", "fax": "650 397 4433", "website": "https://renovorx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.", "fullTimeEmployees": 10, "maxAge": 86400, "priceHint": 4, "previousClose": 1.28, "open": 1.299, "dayLow": 1.1, "dayHigh": 1.3, "regularMarketPreviousClose": 1.28, "regularMarketOpen": 1.299, "regularMarketDayLow": 1.1, "regularMarketDayHigh": 1.3, "beta": 1.028, "forwardPE": -2.682927, "volume": 212557, "regularMarketVolume": 212557, "averageVolume": 52403, "averageVolume10days": 122400, "averageDailyVolume10Day": 122400, "bid": 1.07, "ask": 1.43, "bidSize": 100, "askSize": 200, "marketCap": 26346980, "fiftyTwoWeekLow": 0.531, "fiftyTwoWeekHigh": 3.29, "fiftyDayAverage": 1.23882, "twoHundredDayAverage": 1.229755, "currency": "USD", "enterpriseValue": 21958008, "floatShares": 23488836, "sharesOutstanding": 23951800, "sharesShort": 50787, "sharesShortPriorMonth": 65482, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0021, "heldPercentInsiders": 0.06019, "heldPercentInstitutions": 0.0137600005, "shortRatio": 3.1, "shortPercentOfFloat": 0.0022, "impliedSharesOutstanding": 23951800, "bookValue": 0.105, "priceToBook": 10.476191, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -8051000, "trailingEps": -0.7, "forwardEps": -0.41, "52WeekChange": -0.4634146, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RNXT", "underlyingSymbol": "RNXT", "shortName": "RenovoRx, Inc.", "longName": "RenovoRx, Inc.", "firstTradeDateEpochUtc": 1629984600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "6babfc24-dc5c-3de1-bf9d-2ec73346783e", "messageBoardId": "finmb_236111504", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.1, "targetHighPrice": 8.0, "targetLowPrice": 3.5, "targetMeanPrice": 5.63, "targetMedianPrice": 5.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 4389000, "totalCashPerShare": 0.183, "quickRatio": 4.016, "currentRatio": 4.381, "returnOnAssets": -1.41873, "returnOnEquity": -3.20565, "freeCashflow": -5264875, "operatingCashflow": -9756000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]